Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Operating Expenses: 2023-2025

Historic Operating Expenses for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $60.1 million.

  • Immunome's Operating Expenses rose 12.55% to $60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $243.9 million, marking a year-over-year decrease of 25.55%. This contributed to the annual value of $314.8 million for FY2024, which is 154.83% up from last year.
  • Immunome's Operating Expenses amounted to $60.1 million in Q3 2025, which was up 19.10% from $50.5 million recorded in Q2 2025.
  • Immunome's 5-year Operating Expenses high stood at $133.3 million for Q1 2024, and its period low was $6.8 million during Q1 2023.
  • Moreover, its 3-year median value for Operating Expenses was $50.5 million (2025), whereas its average is $54.2 million.
  • Per our database at Business Quant, Immunome's Operating Expenses soared by 1,850.67% in 2024 and then slumped by 64.33% in 2025.
  • Immunome's Operating Expenses (Quarterly) stood at $98.5 million in 2023, then declined by 12.97% to $85.7 million in 2024, then climbed by 12.55% to $60.1 million in 2025.
  • Its last three reported values are $60.1 million in Q3 2025, $50.5 million for Q2 2025, and $47.6 million during Q1 2025.